Santosh Rao, MD
Hematology & Oncology · Gilbert, AZNPI 1710959739
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Seagen Inc. at 47.1% of the total. Reporting peaked in 2021 at $12,174 and has fallen 56.7% since, to $5,266 in 2025.
Across 84 payments — averaging $295.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$12K
- E.r. Squibb & Sons, L.L.C.$5K
- Astellas Pharma US Inc$4K
- Bayer$3K
- Boston Scientific$157
- Novartis$135
- plus $813 from 22 others
Across 78 payments — averaging $3658.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$102K
- Pfizer$88K
- Merck$57K
- E.r. Squibb & Sons, L.L.C.$28K
- Kyowa Kirin Pharmaceutical Development, Inc$6K
- Kyowa Kirin, Inc.$4K
What the payments were for
- Consulting fees$7,69431%
- Speaking & faculty fees$14,63059%
- Travel & lodging$2851%
- Food & beverage$2,0538%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 12 | $11,704 |
| E.r. Squibb & Sons, L.L.C. | 9 | $5,054 |
| Astellas Pharma US Inc | 7 | $4,033 |
| Bayer | 7 | $2,959 |
| Boston Scientific | 1 | $157 |
| Novartis | 7 | $135 |
| Sanofi | 2 | $111 |
| Merck | 6 | $106 |
| EMD Serono, Inc. | 3 | $55 |
| Pfizer | 4 | $53 |
| Exelixis Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| AstraZeneca | 2 | $44 |
| Caris MPI, Inc. | 2 | $40 |
| Johnson & Johnson | 2 | $39 |
| Eisai Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $28 |
| Foundation Medicine, Inc. | 1 | $26 |
| GSK | 1 | $21 |
| Pharmaessentia USA Corporation | 1 | $21 |
| Amgen | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Incyte Corporation | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PADCEV$15,496
- Nubeqa$2,855
- WATCHMAN Access System$157
- OPDIVO$125
How this compares
$24,855 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 42 | $588,800 |
| CabometyxCabozantinib S-Malate | 11 | $286,137 |
| ErleadaApalutamide | 15 | $224,202 |
| OrgovyxRelugolix | 50 | $171,717 |
| Abiraterone Acetate | 67 | $37,312 |
| EliquisApixaban | 11 | $6,157 |
| Prednisone | 35 | $218 |
| Levothyroxine Sodium | 18 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi | $4,033 | $588,80042 claims |
| Exelixis Inc.Cabometyx | $50 | $286,13711 claims |
| Johnson & JohnsonErleada | $39 | $224,20215 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $48 | $171,71750 claims |
| PfizerEliquis | $53 | $6,15711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Gilbert
- Sumit MadanGilbert$422K
- Jiaxin NiuGilbert$121K
- Yazan SamhouriGilbert$84K
- Matthew UlricksonGilbert$25K
- Qing ZhaoGilbert$25K
- Sujith KalmadiChandler$1.4M
- Jeffrey SchriberScottsdale$715K
- Javier MunozPhoenix$638K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.